Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinengotinib alone or with nab-paclitaxel in advanced solid tumors
NCT04742959Phase 2Completed
- Sponsor
- TransThera Biosciences
- Start
- Mar 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tinengotinib in solid tumor, cholangiocarcinoma (CCA), breast cancer, triple negative breast cancer (TNBC), bladder cancer, sponsored by TransThera Biosciences. Started Mar 2021; status: completed.
02
Drugs
tinengotinib
03
Conditions
solid tumorcholangiocarcinoma (CCA)breast cancertriple negative breast cancer (TNBC)bladder cancer
Beyond the preview
Go deeper on NCT04742959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742959.